Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (591-600 of 745) with videos related to

Pageof 75
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterationsFilip Janku, Tae Min Kim, Gopakumar Iyer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Cell|August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.
Pageof 75

Showing results (591-600 of 745) with videos related to

Sort By:
Pageof 75
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant MelanomaJean-Pierre Delord, Caroline Robert, Marta Nyakas, et al.
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
Journal of the American Academy of Dermatology|July 24, 2023
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapyTeresa Amaral, Oltin Tiberiu Pop, Eftychia Chatziioannou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterationsFilip Janku, Tae Min Kim, Gopakumar Iyer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2021
Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
Cell|August 11, 2018
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
Journal of Translational Medicine|July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
The Lancet. Oncology|February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.
Pageof 75